Assessing Depression in a Geriatric Cancer Population
The goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). Depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. This is a problem because depression can have a negative impact on quality of life. The symptoms of depression are linked to poor health outcomes and higher costs of health care. In fact, depression is one of the top five concerns facing the elderly today.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Assessing Depression in a Geriatric Cancer Population|
- Test the sensitivity and specificity of the Geriatric Depression Scale-Short Form and two other widely used assessments of depression to detect major and minor depression in a geriatric breast and prostate cancer population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To develop a cut-off score for the GDS that is specific to a cancer population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2006|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
150 patients will be women with breast cancer (75 early stage and 75 late stage)
150 will be men with prostate cancer (75 early stage and 75 late stage)
We have a few questionnaires that have been used to measure depression, but we do not know how these measures work with people with cancer. This study will help us answer this question. To complete this study, we need people who may or may not be feeling down or depressed.
If you choose to take part, you will be asked to do the following:
Fill out questionnaires that ask about:
- Your age, eduction, race, and income
- Your mood
In all, these questionnaires will take about 10 minutes to complete.
- Answer questions about your mood. This will also take about 10 minutes to complete.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580476
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Principal Investigator:||Christian Nelson, Ph.D.||Memorial Sloan-Kettering Cancer Center|